NFKB2 Primary Antibody

Item Information
Catalog # Size/Concentration Price
31640 100μg $341.00
Specification
Aliasesp52; p100; H2TF1; LYT10; CVID10; LYT-10; NF-kB2; p49/p100
Clone#2F10A7
Entrez GeneID4791
FormulationPurified antibody in PBS with 0.05% sodium azide
HostMouse
IsotypeIgG2b
ImmunogenPurified recombinant fragment of human NFKB2 (AA: 712-900) expressed in E. Coli.
MW96.7kDa
Species ReactivityHuman
Application
ELISA1/10000
FCM (Flow Cytometry)1/200 - 1/400
Sequence
712-900
Catalog
31640
$341.00
-
+

Contact us to order

Images

Elisa

Cell Culture Products

Figure 1:Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)

Western Blot

Cell Culture Products

Figure 2:Western blot analysis using NFKB2 mAb against human NFKB2 (AA: 712-900) recombinant protein. (Expected MW is 45.9 kDa)

Western Blot

Cell Culture Products

Figure 3:Western blot analysis using NFKB2 mAb against HEK293 (1) and NFKB2 (AA: 712-900)-hIgGFc transfected HEK293 (2) cell lysate.

Flow cytometric

Cell Culture Products

Figure 4:Flow cytometric analysis of Hela cells using NFKB2 mouse mAb (green) and negative control (red).

Product Overview
Description

This gene encodes a subunit of the transcription factor complex nuclear factor-kappa-B (NFkB). The NFkB complex is expressed in numerous cell types and functions as a central activator of genes involved in inflammation and immune function. The protein encoded by this gene can function as both a transcriptional activator or repressor depending on its dimerization partner. The p100 full-length protein is co-translationally processed into a p52 active form. Chromosomal rearrangements and translocations of this locus have been observed in B cell lymphomas, some of which may result in the formation of fusion proteins. There is a pseudogene for this gene on chromosome 18. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2013]

References (references)
References (references) 1.Blood. 2014 Nov 6;124(19):2964-72.
2.Mol Cancer Ther. 2013 Aug;12(8):1629-37.

Please view FAQs here